Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer

Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)

(2020) Aaron C. Tan   Thoracic Cancer

Clinical and Imaging Features of Non-Small Cell Lung Cancer in Young Patients

(2020) Sherief H. Garrana et al.   Clinical Lung Cancer

Targeting KRAS-Mutant Non–Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations

(2020) Timothy F. Burns et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

(2020) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations

(2019) Huijuan Wang et al.   Cancer Medicine

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

(2018) Dejan Juric et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors

(2018) Jordi Rodon et al.   Oncotarget

Tracking the Evolution of Non–Small-Cell Lung Cancer

(2017) Mariam Jamal-Hanjani et al.   NEW ENGLAND JOURNAL OF MEDICINE

LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

(2017) James Chih-Hsin Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials

(2015) Maria Schwaederle et al.   JOURNAL OF CLINICAL ONCOLOGY

Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR

(2015) Sang Yun Ha et al.   Oncotarget

The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement

(2015) Eric I. Benchimol et al.   PLOS MEDICINE

PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies

(2015) Matthias Scheffler et al.   Oncotarget

Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients withPIK3CAmutant advanced solid tumors: preliminary efficacy and safety in patients withPIK3CAmutant ER-positive (ER+) metastatic breast cancer (MBC)

(2014) D Juric et al.   CANCER RESEARCH

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

(2014) D. Sarker et al.   CLINICAL CANCER RESEARCH

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

(2014) Jordi Rodon et al.   INVESTIGATIONAL NEW DRUGS

Characterization of the Novel and Specific PI3K  Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

(2014) C. Fritsch et al.   MOLECULAR CANCER THERAPEUTICS

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC

(2013) Susan Heavey et al.   CANCER TREATMENT REVIEWS

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

(2013) G. I. Shapiro et al.   CLINICAL CANCER RESEARCH

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer

(2013) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Epidermal growth factor receptor mutations in lung adenocarcinoma

(2013) Markus D Siegelin et al.   LABORATORY INVESTIGATION

Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study

(2012) D. Juric et al.   CANCER RESEARCH

Abstract 3749: Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel

(2012) Alan Huang et al.   CANCER RESEARCH

Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma-Rationale for Comprehensive Mutation Profiling

(2011) J. E. Chaft et al.   MOLECULAR CANCER THERAPEUTICS

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

(2010) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL INVESTIGATION

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE